Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)
- Response deadline
- Sep 25, 2029 Due in 1076 days
- Date posted
- Oct 14, 2026
- Source
- Open notice
Description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). Based on the proposed research, applications may be jointly funded with the National Institute of Dental and Craniofacial Research (NIDCR). This is a re-issuance of PAR-23-284 . The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. The research supported through this program must be translational and be based on human biology research using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must reach a translational human endpoint within the project period of the grant.
Classifications
- NAICS93.121
Documents (1)
- PAR-28-022-Full-Announcement.htmltext/html;charset=UTF-8272 KBNot yet available
Contacts
Similar contracts
- Collaborative Program Grant for Interdisciplinary Teams (RM1 Clinical Trial Optional)Due Sep 26, 2029
- Institutional Mentored Career Development Award (Parent K12) (Clinical Trials Not Allowed)Due Jul 12, 2029
- NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)Due Jul 5, 2029
- Causal Hypotheses on the Oral-Systemic Health Impacts of Human Behaviors among People with Chronic Conditions (U01 Clinical Trial Not Allowed)Due Jul 5, 2029
- NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed)Due May 7, 2028
- HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional)Due Nov 23, 2026